Cancer cases are increasing globally, but access to safe, affordable, and effective treatment remains a challenge. Discover how APIs can bridge this gap. Cancer is no longer a rare disease it’s a growing global crisis. According to the WHO, cancer is responsible for nearly 1 in 6 deaths worldwide, and cases are expected to rise by over 60% in the next two decades, especially in developing nations.
Yet, despite this alarming trend, a significant gap remains in access to affordable, high-quality cancer treatments, especially in regions like Africa, South Asia, and Latin America.
As part of the pharmaceutical ecosystem, API manufacturers have a critical role to play not only in ensuring drug availability but also in maintaining the quality, consistency, and regulatory integrity needed for life-saving therapies.
How Cytotoxic Agents Work
Most cancer therapies work by targeting rapidly dividing cells a hallmark of cancer. Cytotoxic agents are specifically designed to:
- Inhibit DNA synthesis or repair
- Interfere with cell replication
- Trigger apoptosis (programmed cell death)
These drugs are especially useful in treating:
- Hematological malignancies (like leukemia)
- Solid tumors (including ovarian, head and neck cancers)
- Genetic disorders like sickle cell anemia
Many oncology APIs act through:
- Ribonucleotide reductase inhibition
- DNA strand break induction
- Free radical generation in cells
references:
- NIH: Mechanism-based strategies for targeted cancer therapy (PMID: 32914350)
- WHO Model List of Essential Medicines (2023 edition)
Application in Functional Formulations
Common Formulation Types:
- Tablets
- Capsules
- Controlled release formats (for improved dosing precision)
Compatibility Considerations:
- Sensitive to heat and moisture requiring coated formulations
- Often combined with antioxidants to reduce degradation
- Require excipients that support long-term stability
Dosage Considerations:
Formulators must balance:
- Potency with tolerability
- Long-term adherence with ease of administration
- Country-specific dosage guidelines
Stability & Quality Considerations
Ensuring consistent therapeutic performance starts with high quality API batches. Key quality control factors include:
- Storage Conditions: APIs should be stored in a cool, dry environment (15–25°C), away from direct light.
- Shelf Life: Typically 24–36 months, depending on formulation and packaging.
- Batch Consistency Tips: Validate assay and impurity profiles batch-to-batch Use HPLC and microbial testing for quality control Maintain detailed CoA documentation for international trade
Global Landscape:
- India (CDSCO): Requires DMF, GMP, and analytical validation
- US FDA: Demands robust data on impurity profiles and stability
- EU EMA: Enforces strict environmental and genotoxicity compliance
Labeling & Claims:
- Cannot claim “cure”
- Must include clear risk and safety warnings
- API exporters must align with pharmacopoeia: IP/USP/EP as applicable
Attention for R&D Teams:
Here are 5 actionable recommendations for R&D, procurement, and formulation teams:
- Partner with reliable GMP-certified API suppliers – Consistency saves cost and protects brand reputation.
- Request complete regulatory dossiers – DMF, MSDS, and CoA are non-negotiable for regulated markets.
- Run forced degradation studies – Simulate long-term storage to design stable FDF.
- Use excipient compatibility mapping – Not all carriers or binders support oncology APIs.
- Establish clear documentation trails – Helps with export registration, audits, and batch recalls.
Conclusion / Summary
As cancer rates climb globally, the world needs more than just research and hospital infrastructure it needs reliable, affordable, and high-quality APIs that make cancer treatment accessible across every border.
Wishrut Pharma stands committed to this mission offering science-backed, quality assured APIs designed for oncology and critical care formulations.
References / Further Reading
- World Health Organization. (2023). Cancer Fact Sheet.
- NIH. Mechanisms of DNA-damaging chemotherapy (PMID: 32914350)
- EMA. European Medicines Agency Oncology Guidelines
- CDSCO Guidelines for API Manufacturers, India (2022)
- USP Monograph — Oncology Active Substances